Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LYR-210 (Lyra Therapeutics, Inc.)
- Development stage
- Unknown
- Lead developer
- Lyra Therapeutics
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
LYR-210 is an investigational, long-acting, drug-eluting nasal insert developed by Lyra Therapeutics for the treatment of chronic rhinosinusitis (CRS). The product is designed to be administered in a simple, in-office procedure and provides sustained release of mometasone furoate, a potent corticosteroid, directly to the sinonasal mucosa for up to six months. LYR-210 utilizes the company's proprietary XTreo platform, which consists of a bioresorbable, mesh-like polymeric matrix that expands to fit the patient's anatomy. By providing continuous, localized anti-inflammatory therapy, LYR-210 aims to provide an alternative to daily nasal sprays or repeat surgical interventions for patients who remain symptomatic despite conventional medical management.
- Other names
- mometasone furoate drug-eluting insertLYR-210 bioresorbable insertLYR210 bioresorbable insertLYR 210 bioresorbable insert
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on LYR-210 (Lyra Therapeutics, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LYR-210 (Lyra Therapeutics, Inc.).